Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors

Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors

This single center, single arm and prospective study aimed to establish gene mutation database and select the neoantigens in patients with advanced malignant melanoma, bladder cancer and colorectal cancer. Then, we intended to explore the safety and efficacy of individual tumor antigen-sensitized DC vaccine and their sensitized T cells in these solid cancers.

Inclusion Criteria:

• Age:18-75 years
• Pathologically diagnosed advanced (stage IV) malignant melanoma, bladder cancer or colorectal cancer with measurable lesions;
• Failed in the previous standard therapy;
• ECOG PS (Eastern Cooperative Oncology Group performance status) score 0-2 points;
• The estimated survival period is ≥3 months;
• Rehabilitate from previous therapy;
• Adequate organ functions;
• Patient's written informed consent;

Exclusion Criteria:

• Tumor emergencies;
• Abnormal coagulation function;
• Contagious diseases, such as HIV, HBV, HCV infection;
• Mental disorders;
• Concomitant tumors;
• Immunological co-morbidities